Trv Gp Iv, LLC Tango Therapeutics, Inc. Transaction History
Trv Gp Iv, LLC
- $88.8 Million
- Q2 2025
A detailed history of Trv Gp Iv, LLC transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Trv Gp Iv, LLC holds 16,859,075 shares of TNGX stock, worth $115 Million. This represents 97.21% of its overall portfolio holdings.
Number of Shares
16,859,075
Previous 16,859,075
-0.0%
Holding current value
$115 Million
Previous $23.1 Million
273.74%
% of portfolio
97.21%
Previous 88.92%
Shares
3 transactions
Others Institutions Holding TNGX
# of Institutions
123Shares Held
117MCall Options Held
245KPut Options Held
18.9K-
Tcg Crossover Management, LLC Palo Alto, CA10.7MShares$73.2 Million11.21% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA10.6MShares$72.5 Million4.69% of portfolio
-
Farallon Capital Management LLC San Francisco, CA9.16MShares$62.5 Million0.21% of portfolio
-
Woodline Partners LP San Francisco, CA6.03MShares$41.1 Million0.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.91MShares$40.3 Million0.05% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $601M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...